Liraglutide Eases Depression in Mice via 2-AG Gut Pathway, Independent of GLP-1 Receptors
Updated
Updated · Inside Precision Medicine · Jun 9
Liraglutide Eases Depression in Mice via 2-AG Gut Pathway, Independent of GLP-1 Receptors
3 articles · Updated · Inside Precision Medicine · Jun 9
Summary
Cell Host & Microbe research found liraglutide reduced depressive-like behavior in mice even when GLP-1 receptors were absent, pointing to a noncanonical antidepressant mechanism.
Liraglutide increased Lactobacillus delbrueckii in the gut by boosting bacterial serine and phosphoenolpyruvate biosynthesis, changes that supported microbial growth.
Higher L. delbrueckii levels raised diacylglycerol and then 2-arachidonoylglycerol, or 2-AG, which dampened stress-driven neuronal hyperactivity in the basolateral amygdala and dorsomedial hypothalamus.
The findings suggest a microbiota-endocannabinoid axis could help explain mixed prior evidence on GLP-1 drugs and depression while expanding their potential beyond diabetes and obesity treatment.
Researchers said the preclinical results could support drug repurposing and are especially relevant because metabolic and psychiatric disorders often occur together.
Could a popular weight-loss drug's secret antidepressant effect actually be in our gut?
If a probiotic can mimic this drug's mental health benefits, is a new depression therapy on the horizon?
From Diabetes Drug to Antidepressant: How Liraglutide’s Gut-Brain Axis Could Revolutionize Depression Therapy
Overview
Recent research has revealed that liraglutide, a drug commonly used for diabetes and weight loss, can reduce depression symptoms in mice through a newly discovered gut-brain pathway. This pathway works independently of the drug’s usual GLP-1 receptor activation, challenging previous beliefs about how such medications affect the brain. The finding not only highlights the important role of the gut in mental health but also opens up new possibilities for developing depression treatments that target the gut-brain connection, moving beyond traditional approaches focused only on the brain.